CTRI/2015/01/005427招募中未知
A randomized, multicentric, open label, single dose, two treatment, two sequence, two period, crossover, bioequivalence study of test methotrexate tablets USP 15 mg (from Zhejiang Hisun Pharma Co. Ltd., China) with reference Trexall® (Methotrexate tablets USP) 15 mg of Barr Pharmaceuticals, USA in 46 adult, patients suffering from psoriasis under fasting condition
Zhejiang Hisun Pharma Co Ltd0 个研究点目标入组 46 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Adult patients suffering from psoriasis; aged between 18 to 45 years (both inclusive)
- •2.Patients should already be receiving 15 mg once weekly for psoriasis
- •3.Patients willing to voluntarily provide written informed consent.
- •4.Patients willing to undergo pre and post-study physical examinations and laboratory investigations.
- •5.Patients willing to adhere to protocol and they should not consume coffee, tea, chocolate, grape fruit juice or soft drink at least 24 hours prior to investigational product administration (i.e. in house monitoring and the remaining based on history) and during their clinical stay in each study period.
- •6.Patient should be willing to adhere to the protocol and they should not consume alcohol at least 48 hours prior to dosing (i.e. in-house monitoring and the remaining based on history) and should agree not to take any amount of alcohol during the study period.
排除标准
- •1.Patients incapable of understanding the informed consent process.
- •2.Pregnant [female patients with a positive pregnancy test at screening or positive serum β-HCG test (done at Check-in of each study period)] or lactating females
- •3.Female patients of childbearing potential who is unwilling or unable to use an appropriate method of contraception, at least 14 days prior to the first dose of study medication until the poststudy follow-up (i.e. 7 days after the last dosing in Period II). Female patients using hormonal contraceptives either oral or implants.
- •4.Female patients with history of dysmenorrhea requiring medication
- •5.Patients with inadequate venous access in their left or right arm to allow the collection of all samples via venous cannula in the study
- •6.Patients with evidence of psychiatric disorder likely to limit the validity of consent to participate in the study, or limit the ability to comply with the protocol requirements.
- •7.Patients with any evidence of organ dysfunction or any clinically significant deviation from normal in their physical or clinical evaluation including ECG and X-ray results.
- •8.Any treatment which could affect the pharmacokinetic of methotrexate (salicylates, hypoglycaemics, diuretics, sulphonamides, diphenylhydantoins, tetracyclines, chloramphenicol and p-aminobenzoic acid, the acidic anti-inflammatory agents, probenecid, penicillins, Chloroquine, omeprazole, etretinate, co-trimoxazole and trimethoprim etc.) administered within 1 month of starting of study/in past 1 month.
- •9.Patients with history of drug hyper sensitivity to methotrexate or related drugs or to any of the excipient of the formulation
- •10.Patients with a history of alcohol, found with current alcohol abuse based on Alcohol breath test and with history of drug abuse, found urinary screen test positive for drugs of abuse (Amphetamines, Morphine, Benzodiazepines, Marijuana, Cocaine and Barbiturates).
- •11.Patients who are diagnosed to be HIV 1 and 2 or Hepatitis B (HBsAg) or Hepatitis C (HCV) virus reactive/positive.
- •12.Patients with clinically significant abnormal haemoglobin (Hb), total white blood cells count (WBC), differential WBC count, platelet count and hematocrit
- •13.Patients who, have clinically significant abnormal laboratory values for serum creatinine, blood urea nitrogen, (BUN), serum aspartate aminotransferase (AST), serum alanine aminotransferase
- •(ALT), serum alkaline phosphatase (ALP), c-glutamyltranspeptidase, serum bilirubin, serum glucose (fasting) etc.
- •14.Patients with clinically significant abnormal urine analysis, defined as the presence of RBC (5/HPF), pus cells (5/HPF), epithelial cells (5/HPF), glucose (positive), ketones (positive), bilirubin (positive) and protein (positive)
- •15.Patients with clinically significant abnormal results during ultrasonographic examinations.
- •16.Patients with a clinically significant past history or current medical condition of:
- •Pulmonary disorders (COPD and asthma)
- •Cardiovascular disorders (especially cardiac blocks)
- •Neurological disorders (especially seizures, migraine)
- •GIT disorders including history or presence of significant gastric and/or duodenal ulceration
- •Renal and/or hepatic disorders
- •Coagulation disorders
- •Endocrine disorders (especially diabetes mellitus)
- •History or pre
研究者
相似试验
招募中
不适用
A clinical trial to study the effects of two drugs, Methotrexate tablets USP 2.5 mg / Rheumatrex® in Patients with suffering from psoriasis.CTRI/2015/02/005506Zhejiang Hisun Pharma Co Ltd42
Unknown
Unknown
Bioequivalence (BE) study of Chemi Ferric Carboxymaltose Injection 750 mg/15 mL versus Injectafer® (Ferric Carboxymaltose Injection) 750 mg/15 mL in adult patients with iron deficiency anemia under fasting condition.CTRI/2023/10/058814ITALFARMACO S.p.A.
已完成
不适用
A Study to Assess Bioequivalence of Albumin-Bound-Paclitaxel Formulations in Female Participants with Advanced Breast CancerCTRI/2022/07/043652Intas Pharmaceuticals Ltd India
进行中（未招募）
1 期
A study of XOMA 213 in the reduction of breast milk production in women after child birth.Suppression of Lactation after Delivery in Postpartum WomenEUCTR2015-005751-27-ESXOMA (US) LLC
招募中
Unknown
PK Study of Ferric Carboxymaltose injection in Iron deficiency anemia patients.CTRI/2023/07/054917Orbicular Pharmaceutical Technologies Pvt Ltd